New Horizons in Nuclear Cardiology: Imaging of Peripheral Arterial Disease.

Autor:	Callegari S; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine; Vascular Medicine Outcomes Program, Yale University, New Haven, CT, USA., Mena-Hurtado C; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine; Vascular Medicine Outcomes Program, Yale University, New Haven, CT, USA., Smolderen KG; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine; Vascular Medicine Outcomes Program, Yale University, New Haven, CT, USA; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA., Thorn S; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine., Sinusas AJ; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, United States; Department of Biomedical Engineering, Yale University, New Haven, CT, United States. Electronic address: albert.sinusas@yale.edu.
Jazyk:	angličtina
Zdroj:	Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology [J Nucl Cardiol] 2024 Nov 14, pp. 102079. Date of Electronic Publication: 2024 Nov 14.
DOI:	10.1016/j.nuclcard.2024.102079
Abstrakt:	Lower extremity peripheral artery disease (PAD) is characterized by impairment of blood flow associated with arterial stenosis and frequently coexisting microvascular disease and is associated with high rates of morbidity and mortality. Current diagnostic modalities have limited accuracy in early diagnosis, risk stratification, preprocedural assessment, and evaluation of therapy and are focused on the detection of obstructive atherosclerotic disease. Early diagnosis and assessment of both large vessels and microcirculation may improve risk stratification and guide therapeutic interventions. SPECT and PET imaging have been shown to be accurate to detect changes in perfusion in preclinical models and clinical disease, and have the potential to overcome limitations of existing diagnostic modalities, while offering novel information about perfusion, metabolic, and molecular processes. This review provides a comprehensive reassessment of radiotracer-based imaging of PAD in preclinical and clinical studies, emphasizing the challenges that arise due to the complex physiology in the peripheral vasculature. We will also highlight the latest advancements, underscoring emerging artificial intelligence and big data analysis, as well as clinically relevant areas where the field could advance in the next decade. Competing Interests: Declaration of Competing Interest ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Albert Sinusas reports financial support was provided by NIH. Albert Sinusas reports a relationship with National Institutes of Health that includes: funding grants. Albert J. Sinusas reports Institutional grants from Jubilant and Siemens; individual consulting fees unrelated to PET imaging compounds from MicroVide, LLC; patents related to SPECT imaging agent RP805 for MicroVide, LLC; member Cardiovascular Council of SNMMI (no funds received); receipt of equipment, materials, drugs, or other services from Lantheus (MTA LMI1195) and Jubilant (Rb-82 generator). The other authors declare no relevant conflict of interest. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Dr. Mena-Hurtado reports unrestricted research grants from Philips and Shockwave and is a consultant for Abbott Vascular, Cook, Optum Labs. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Stephanie Thorn has declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Dr. Smolderen reports unrestricted research grants from Philips, Merck, Shockwave, and Johnson & Johnson; she is a consultant for Optum Labs, Cook, Tegus, Twill Inc. and Abbott Vascular. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Santiago Callegari has declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 American Society of Nuclear Cardiology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu